References
- Bajo M A, Selgas R, Miranda B, et al. Medium term response to H-R erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity. Adv Perit Dial 1991; 7: 296–300
- Besarab A, Besarab F M, Miller D. Effects of dialysis factors and route of administration on response of hemodialysis patients to recombinant human erythropoietin. ASAIO Trans 1991; 37: 181–182
- Besarab A, Golper T A. Response of continuous peritonea] dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients. ASAIO Trans 1991; 37: 395–396
- Cheng I K, Cy C, Chan M K, Yu L, Fang G X, Wei D. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study. Clin Nephrol 1991; 35: 207–212
- Eschbach J W. Erythropoietin 1991–an overview. Am J Kidney Dis 1991; 18(Suppl. 1)3–9
- Hughes R T, Cotes P M, Pippard M J, et al. Subcutaneous administration of recombinant human erythropoietin to subject on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment. Br J Haematol 1990; 75: 268–273
- Lui S F, Law C B, Ting S M, Li P, Lai K N. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1991; 36: 246–251
- Macdougall I C, Roberts D E, Neubert P, Dharmasena A D, Coles G A, Williams J D. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; 1: 425–427
- Macdougall I C, Hutton R D, Coles G A, Williams J D. The use of erythropoietin in renal failure. Postgrad Med J 1991; 67: 9–15
- Rafferty J, Norling R, McMath C, Tamaru R, Morgan-stein D. Stat Works (Version 1.1). Heyden and Son LTD, London 1985, Cricket Software
- Saleh A, Krane N K, Caballero M, Starks E. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD. Adv Perit Dial 1991; 7: 288–291
- Stevens J M, Auer J, Strong C A, et al. Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991; 6: 487–494
- Stockenhuber F, Loibl U, Gottsauner Wolf M, et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 399–402
- Zappacosta A R, Perras S T, Bell A. Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure. Am J Med Sep, 1991; 91: 229–232
- Zehnder C, Blumberg A. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: Comparison between intravenous and subcutaneous administration. Nephron 1991; 57: 485–486
- Lundberg L. Blood-membrane interaction and treatment of haemodialysis patients. A study of various factors. Doctorial Thesis, Umeå University, Sweden 1994, S-901 87 Umeå